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Abstract: Bile acid sequestrants (BAS) represent a therapeutic approach for the 
management of hypercholesterolemia that relies on the cationic polymeric nature of BAS 
to selectively bind negatively charged bile acids. We hypothesized that the cross-linking of 
β-cyclodextrin (β-CD) and saccharides such as starch or dextrin with divinyl sulfone 
(DVS) yields homo- and hetero-polymeric materials with the ability to trap sterols. Our 
hypothesis was put to test by synthesizing a library of 22 polymers that were screened to 
evaluate their capability to sequester both cholesterol (CHOL) and cholic and deoxycholic 
acids (CA and DCA). Three polymers synthesized in high yield were identified as 
promising. Two were neutral hetero-polymers of β-CD and starch or dextrin and the third 
was a weakly cationic homo-polymer of starch, highlighting the importance of the cavity 
effect. They were tested in hypercholesterolemic male Wistar rats and their ability to 
regulate hypercholesterolemia was similar to that for the reference BAS cholestyramine, 
but with two additional advantages: (i) they normalized the TG level and (ii) they did not 
increase the creatinine level. Neither hepatotoxicity nor kidney injury was detected, further 
supporting them as therapeutical candidates to manage hypercholesterolemia. 
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1. Introduction 
Cardiovascular diseases (CVD) are the leading cause of death in developed countries [1]. The root 
of clinical practice guidelines for these diseases is based on the definition of reference values and the 
measurement of traditional risk factors that, however, have been redefined and set lower over time. 
Hypercholesterolemia, an elevation of the total cholesterol (CHOL) and/or low-density lipoproteins 
(LDL) in the blood, is one such risk factor. This disorder leads to the accumulation of atheromatous 
plaques that is especially relevant when it takes place on the coronary arteries, narrowing them and 
reducing the blood flow supplied to the myocardium. The management of hypercholesterolemia is 
addressed by non-pharmacological approaches involving the modification of some risk factors, such as 
unhealthy diet, physical inactivity and tobacco, which very frequently need to be accompanied by 
pharmacological therapy [2]. The therapeutic approaches can be divided into statin and non-statin 
strategies [3,4]. Statins are competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase 
(HMGCoA-R), a key rate-limiting enzyme of the CHOL biosynthetic pathway and they are the  
first-line pharmacological therapy because the biosynthesis of CHOL accounts for up to two-thirds of 
the CHOL pool of the body [5]. Non-statin drugs comprise niacin, fibrates, bile acid sequestrants 
(BAS) and natural extracts, being their nature and mechanisms of action diverse [5].  
BAS exploits the fact that nearly 50% of the CHOL catabolism is governed by its conversion into 
bile acids (BA) to disrupt the reabsorption and favor their excretion, which in normal conditions is 
limited to about 5% [6,7]. In general, BAS are cationic polymeric hydrogels that selectively binds the 
negatively charged BA. However, fibers from daily diet show some capability of binding BA and 
polysaccharides have been used as starting materials to produce BAS due to their hydrophilicity, low 
toxicity and biocompatibility [8]. Thus, it has been reported the ability to sequester BA of dextran 
cross-linked with epichlorohydrin [9,10], methylans [11] or chitosan [12,13] functionalized with 
alkylammonium groups. 
The ability of cyclodextrins (CDs) to form inclusion complexes is old knowledge and has found 
pharmaceutical applications [14,15]. In the context of BAS, the therapeutic potential of CDs to balance 
the CHOL homeostasis has been explored in animal models [16–21]. Thus, mice injected with  
[14C] chenodeoxycholate and [3H]cholate showed increased excretion of [14C] chenodeoxycholate in 
feces when they were fed with β-CD, whereas the effect of α-CD or γ-CD was neutral. However, 
cholestyramine, an anion-exchange resin currently used in hypercholesterolemia therapy as BAS, 
increased the radioactivity of both [14C] chenodeoxycholate and [3H]cholate [22]. Further studies have 
demonstrated that the ingestion of β-CD enhances the BA excretion without provoking depletion of 
lipophilic vitamins [16] and that the primary mechanism of the lipid lowering potential of β-CD seems 
to be consequence of its sterol binding capacity that leads the impaired reabsorption of circulating BA 
and intestinal adsorption [17]. Interestingly, α-CD has been demonstrated to reduce the absorption of 
saturated fatty acids from the diet, which promote the hepatic synthesis of CHOL and reduce its 
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clearance, with the net effect of reducing the total CHOL in blood. This result paved the way for 
ongoing clinical trial in human [23]. 
CD-based polymeric materials are interesting by their biomedical and pharmaceutical applications [24]. 
They have been synthesized by cross-linking with epichlorohydrin, diepoxide, diisocyanate or 
anhydride mediated cross-linkers. In addition, these host materials have been prepared by combining 
polymers and CDs as for example the copolymerization of vinyl or (meth)acryloyl-modified CD monomers 
with vinyl monomers (acrylic acid, 2-hydroxyethyl methacrylate or N-isopropylacrylamide) [24]. 
More recently, citric acid has been used as a cross-linker for the synthesis of drug delivery  
polymers [25–28] and in a previous contribution of this volume we reported the synthesis of divinyl 
sulfone (DVS) cross-linked CD-based polymeric materials and their applications as sorbents and 
encapsulating agents [29]. 
Despite the potential of β-CD as a BAS and the wide range of options to polymerize it, to the best 
of our knowledge there is only a single report on the application of insoluble β-CD polymers to the 
sorption of bile salts [30]. In this work we explore the applications of the DVS cross-linked-based  
polymers [29] as BAS. We hypothesize that the homo- and hetero-polymeric materials obtained by the 
cross-linking of either β-CD and/or polysaccharides such as starch or dextrin with DVS should also 
have the ability to trap sterols and that those matrices may be of help to manage hypercholesterolemia. 
2. Results and Discussion 
The elevation of total CHOL and/or LD in blood (i.e., hypercholesterolemia) is a risk factor in 
CVD. CHOL metabolism in humans shows two important features from the perspective of the design 
of compounds to manage hypercholesterolemia: (i) dietary CHOL is the only alternative to 
biosynthesis as source of CHOL in mammals, representing about 35% of the CHOL in plasma [31] and 
(ii) about 50% of the CHOL catabolism is directed to its conversion into BA [6,32]. Thus, compounds 
with the ability to sequester both BA and dietary CHOL are potential drug candidates to lower CHOL 
levels. In this context, the ability of CD to form inclusion complexes with CHOL and BA has not been 
exploited, despite it is old knowledge and animal models have demonstrated that the intake of β-CD 
enhances BA excretion and lowers TG levels [16–20]. To the best of our knowledge, there is a single 
report on the application of insoluble β-CD polymers to the sorption of bile salts [30], but since they 
were functionalized with alkyl quaternary ammonium groups to yield cationic materials as the classical 
BAS drugs cholestyramine, colestipol, colesevelam, colextran or colestilan [8], the ability of β-CD to 
form inclusion complexes cannot be accounted for by their mechanism of action. These facts led us to 
hypothesize that the cross-linking β-CD may yield insoluble polymeric materials with ability to trap 
both dietary CHOL and BA that may help in the management of hypercholesterolemia.  
In order to put to test our hypothesis, a library of 22 insoluble saccharide-based polymers was 
synthesized by cross-linking either β-CD and/or polysaccharides, such as starch or dextrin, with DVS. 
The selection of DVS as a cross-linker was based on its good hydrosolubility, allowing the synthesis of 
the polymers in water, as well as its reactivity as an excellent Michael acceptor, consequence of the 
sulfone’s electron withdrawing capability that makes it a good electrophile [33,34]. The library was 
designed to evaluate both the cavity effect and the ionic effect. The former allows the formation of 
inclusion complexes with apolar molecules whereas the latter promotes the electrostatic interactions 
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with charged molecules. Thus the library consists not only of cross-linked β-CD polymers but also 
dextrin and starch homo-polymers as well as β-CD/dextrin and β-CD/starch hetero-polymers, and some 
of them were functionalized with two aliphatic amines (diethylamine and bis(2-hydroxyethyl)amine) 
or with one aromatic amine (bis(2-pyridylmethyl)amine). 
The library was screened against a solution of CHOL and a solution of cholic acid (CA) and 
dexoxycholic acid (DCA) to evaluate the ability of the polymers to sequester both diet CHOL and BA. 
At this point, it is important to recall that the solution of CA-DCA is a good model system because CA 
is the most abundant in bile, being its relative abundance 37.5% (25% for DCA), and the affinity of  
β-CD for them is among the lowest for the BA [22]. In fact, animal experimentation has revealed that 
the ingestion of β-CD promotes the excretion of chenodeoxycholate and decreases the percentage of 
taurochenodeoxycholate in biliary bile acids by −75% [17,22]. The result of the screening is 
summarized in Figure 1 and reveals some general trend. First, compared to cholestyramine (sample 1), 
a reference ion-exchange resin currently used in hypercholesterolemia therapy as BAS, polymers show 
lower performance as expected considering the reported poor affinity of β-CD for CA [22,35]. Second, 
for homo-polymers (samples 2–7) β-CD yields the best material regardless of the degree of  
cross-linking (samples 4 and 7). In general, those polymers with lower degree of cross-linking show 
better sorption for BA than their high cross-linked counterparts (samples 2–4 vs. 5–7). Hetero-
polymers also show a good performance (samples 8 and 11) with even higher ability to trap the BA. 
Third, the functionalization of the polymers with amines to favor electrostatic interactions with BA did 
not produce a clear general pattern. For the particular case of low cross-linked β-CD polymers, the 
functionalization of the homo-polymer (sample 7) with aliphatic amines (samples 9 and 17) yields an 
increase in the sorption of CA-DCA in detriment of CHOL, whereas for hetero-polymers (samples 8 
and 11), the functionalization with a aliphatic amines (samples 19 and 18) or with the aromatic amine 
(samples 23 and 22) does not present any remarkable advantage. 
Some polymers show features that make them good candidates for animal experimentation. 
Polymers 9, 11 and 17 share about 70% of the capacity of cholestyramine to sequester both CA and 
DCA (30-32 µmol/g vs. 44 µmol/g) pointing them out as potential BAS drugs. Additionally  
polymers 4 and 21 preferentially bind CHOL and may be potential food additives to reduce the 
absorption of CHOL. This may be an important approach in patients with altered CHOL homeostasis 
by increased CHOL absorption since they may not benefit from statin treatment, but may actually 
increase their cardiovascular risk when treated with drugs that reduce endogenous cholesterol  
synthesis [36]. Additionally, polymers 8 and 9 show similar capacity for CHOL and BA and may 
constitute a third category of attractive compounds that act simultaneously on the absorption of dietary 
CHOL and on the excretion of BA. However, the ability to sequester BA and CHOL is not the only 
factor to consider, since the yield of the synthesis is a critical parameter to take into account. Thus, for 
each group only the polymer that was synthesized with the highest yield was selected for animal 
experimentations: polymer 11 (19.4% yield vs. 7.6% and 2.2%) from the group of potential BAS, 
polymer 21 (61.3% yield vs. 57.4%) from the group of potential food additive, and polymer 8 (58.21% 
yield vs. 7.9%) from the third category. 




Figure 1. Screening against a solution of cholesterol (CHOL) and a solution of cholic and deoxycholic acids (CA and DCA) of the library 
prepared by cross-linking of β-CD (C), dextrin (X), starch (S) with a high (h) or low (l) DVS:saccharide stoichiometry and eventually with 
bis(2-pyridylmethyl)amine (BPY), bis(2-hydroxyethyl)amine (DOH) or diethylamine (DE). Each polymer is defined by a number and in 
brackets a summary of its composition. Units of the primary y-axes are μmoles of CHOL, CA and DCA per gram of polymer and % yield. 
Polymers encircled were assayed in vivo on hypercholesterolemic Wistar rats. 
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Polymers 8 and 11 are neutral hetero-polymers of β-CD and starch or dextrin and their good 
performance can be justified taking into account the ability of CD to sequester both CHOL from the 
diet and BA [37,38]. However, the rationalization of the results obtained with polymer 21, a charged 
homo-polymer of starch bearing bis(2-pyridylmethyl)amine, may not be so straightforward. It is well 
established that amylose, one of the two components of starch, forms helical structures with a central cavity 
that can accommodate guest molecules [39], having been proposed to act as binding sites for BA [22]. 
The synthesis of the above polymers was scaled up and unreacted components were eliminated by 
Soxhlet extraction with ethyl acetate. After drying in a vacuum oven, polymers were characterized. 
Elemental analysis (Table 1) revealed a similar percentage of sulfur, suggesting a comparable degree 
of cross-linking. The content of nitrogen supports the idea that compared to cholestyramine  
polymer 21 is a weak cationic material and that polymers 8 and 11 are neutral.  
Table 1. Elemental analysis of the polymers selected [8 (l-CS), 11 (l-CX) and 21 (l-S_BPY); 
l = low DVS:saccharide stoichiometry, C = β-CD, X = dextrin, = starch; BPY =  
bis(2-hydroxyethyl)amine] for animal experimentation. 
Compound % N % C % S 
Cholestyramine 5.6 ± 0.11 63.4 ± 0.15 - 
Polymer 8 - 39.9 ± 0.05 9.5 ± 0.11 
Polymer 11 - 40.3 ± 0.14 8.6 ± 0.03 
Polymer 21 0.4 ± 0.06 41.1 ± 0.00 8.5 ± 0.00 
Powder X-ray diffraction patterns show a broad hump at 2θ = 13°–23° that indicates that the 
polymers, as well as cholestyramine, exist in a form of non-crystalline state (Figure 2). 
 
Figure 2. X-ray diffraction patterns of the polymers selected [8 (l-CS), 11 (l-CX) and 21 
(l-S_BPY); l = low DVS:saccharide stoichiometry, C = β-CD, X = dextrin, = starch; BPY 
= bis(2-hydroxyethyl)amine] for animal experimentation.  
SEM images (Figure 3) reveals that the surface morphology is characteristic for each sample. 
Cholestyramine exhibits a rather homogeneous surface compared to cross-linked polymers and the 
presence of starch or dextrin seems to have a direct influence on the surface, those containing starch  
(B and C) being more irregular than that with dextrin (D vs. C). 








Figure 3. Electron microscopy analysis. Low (left) and high (right) resolution 
micrographs of the cationic polymers cholestyramine (A), polymer 21 (B), and neutral 
polymers 8 (C) and 11 (D), being the magnification ×2000 (A1), ×20,000 (A2),  
×2500 (B1), ×15,000 (B2), ×7500 (C1), ×24,000 (C2), ×6000 (D1), ×13,000 (D2).  
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In vivo analysis of cholestyramine and polymers 8, 11 and 21 was carried out on 
hypercholesterolemic male Wistar rats. Hypercholesterolemia was induced by supplementing 
conventional diet with a 2% (w/w) CHOL (hypercholesterolemic diet) for two weeks. Then animals 
were fed with the hypercholesterolemic diet supplemented with 5% (w/w) of the polymer to be 
assayed. During the experiment, the weight of the animals increased up to a 170% during the first  
two weeks and then an additional 130% during the last two weeks, no relevant difference being found 
between the control group (i.e., fed with conventional diet) and the others. At the end of the four weeks 
rats were sacrificed and a pool of clinical chemistry parameters analyzed. Results are summarized in 
Table 2. Comparison with the literature is not straightforward due to difference in detection 
techniques, animal age or feeding, among other variables [40]. Thus, according to the Taconic 
Technical Library, the mean reference value for cholesterol is 2.1 mmol/L for male and 2.4 mmol/L for 
female, whereas Boehm et al. report 1.5 mmol/L for both male and female [40]. This discrepancy is 
found in almost any of the chemical analytes compared and remarks the importance of control animals 
to evaluate the course of the experiment. The reference value of our control group (i.e., animals fed 
with conventional diet) was 1.93 mmol/L, which is within the reported values and closer to that of the 
Taconic Technical Library [40]. 
Table 2. Clinical chemistry analysis. Mean values and standard deviation from the five 
animals comprising each group. Those parameters whose differences with the control 
group are statistically significant are shown in bold and the resulting p-values in brackets. 
Animals were fed with conventional diet (control), conventional diet supplemented with 
2% (w/w) CHOL (diet), or with diet for two weeks and two extra weeks with diet 
supplemented with 5% cholestyramine or polymers 8 (l-CS), 11 (l-CX) and 21 (l-S_BPY); 





















(p < 0.02) 
1.25 ± 0.23  
(p < 0.01) 
63.65 ± 7.96 
(p < 0.05) 
156.0 ± 
72.89 
60.0 ± 9.06 0.99 ± 1.58 9.31 ± 3.34 
Cholestyramine 1.8 ± 0.32 
1.98 ± 0.83  
(p < 0.02) 
64.53 ± 6.19 
(p < 0.01) 
161.2 ± 8.59 
74.0 ± 
30.18 
1.36 ± 1.58 11.01 ± 1.83 




0.82 ± 0.22 58.22 ± 9.72 
102.4 ± 
13.20 









1.47 ± 1.01 
6.07 ± 0.34 
(p < 0.01) 
Frequently hypercholesterolemia is accompanied by increased TG levels and the treatment of 
hyperlipidemic patients with BAS resins may provoke additional hypertriglyceridemia as the result of 
the increase of VLDL-TG levels [41]. A detailed analysis of Table 2 reveals that hypercholesterolemia 
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was successfully induced and the values of both CHOL and TG detected in the control group of 
animals that did not received any compound were 1.4-fold and 1.7 fold, respectively, higher than the 
group of animals fed with conventional diet, these differences being statistically significant  
(p-value < 0.02 and < 0.01, respectively). Groups whose diet was supplemented with either polymers 
or cholestyramine showed similar depressed levels of CHOL, but TG in blood were dependent on the 
treatment. Thus, polymers regularized the TG levels down to the control group fed with conventional 
diet, whereas cholestyramine induced a 1.6 fold increase. This result is statistically significant  
(p-value < 0.01) and in full agreement with other studies that report that cholestyramine increases the 
level of TG [42] whereas CDs reduce triglyceridemia [16,18,43]. 
There exist some controversial results on the toxicity of ingested CD. Thus, while α-CD is 
undergoing clinical trial for decreasing serum CHOL in humans [23], 5% β-CD has been reported to 
increase both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity and to 
provoke cell necrosis in rats [18]. The results of the animal experimentation (Table 2) show that the 
selected polymers do not alter transaminase activity in blood, being the values similar to those of the 
control group fed with conventional diet except that of gamma-glutamyltransferase (GGT) for  
polymer 8. GGT activity has been reported as highly specific for the diagnostic of bile duct cell 
necrosis [44], but the comparison with the control group did not achieve statistical significance  
(0.1 < p-value < 0.05). The analysis of creatinine (i.e., acute kidney injury) reveals normal values.  
At this point it is important to recall that cholestyramine yielded the highest creatinine level and that 
this increase is statistically significant (p-value < 0.01). Considering that cholestyramine is a drug 
currently in use to manage hypercholesterolemia and that its safety has been assayed, the better values 
of polymers 8, 11 and 21 suggest that a priori their toxicity does not invalidate them as candidates to 
manage hypercholesterolemia. 
3. Experimental Section 
3.1. Materials 
Native β-CD (95%) was bought from TCI Europe N.V. (Zwijndrecht, Belgium) and both dextrin 
and starch from Fluka (Madrid, Spain). DVS (97%), CHOL (95%), DCA (99%) and CA (98%) were 
purchased from AlfaAesar (Karlsruhe, Germany). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid), diethylamine, Bis(2-pyridylmethyl)amine and bis(2-hydroxyethyl)amine were acquired from 
Sigma-Aldrich (Madrid, Spain). Animals and conventional diet were obtained from Harlan  
(Barcelona, Spain). 
3.2. Synthesis of a Library of BAS Polymers 
3.2.1. Neutral Homo-Polymers  
Starch, dextrin or β-CD (10 g) was dissolved in carbonate buffer (0.5 M, pH 12, 500 mL) under 
magnetic stirring at room temperature. For the particular case of starch, the complete solubilization 
required heating to reflux (15–20 min) and then time to reach room temperature. The stirring was 
continued for 30 min prior to the addition of either 10 or 5 mL of DVS to yield a DVS:Glc molar ratios 
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of 2:1 or 1:1, respectively. The cross-linking reaction was allowed to proceed (7–8 h) resulting in a 
solid powder that precipitates from the reaction media. The product was isolated by filtration, 
thoroughly washed with deionized water and then with MeOH and diethyl ether. The resulting  
cross-linked carbohydrate polymer was dried in vacuo for 18 h at 50 °C. 
3.2.2. Neutral Hetero-Polymers  
β-CD (5 g) and starch, dextrin (5 g) were copolymerized with DVS (5 mL, DVS:Glc 1:1 molar 
ratio). The cross-linking reaction and the isolation of the product was carried out as described above. 
3.2.3. Charged Homo- and Hetero-Polymers  
Polymers were prepared as described above. Charge was introduced by addition of 25 mmol of 
bis(2-pyridylmethyl)amine, bis(2-hydroxyethyl)amine or diethylamine and after 1.5 h of cross-linking 
reaction. The copolymerization reaction was allowed for 6–7 h prior the isolation of the polymer. 
3.3. Analysis of the Sequestrant Capability of the Library of BAS Polymers 
Polymers were powder and homogenized with a mortar and pestle prior the assay. The polymer  
(0.5 g) was incubated for 1 h at 37 °C with either 5 mL of a solution of CA (3 mM) and DCA (2 mM) 
in 25 mM HEPES pH 7.5, 2.5% DMSO (v/v) or with 5 mL of CHOL (5 mM) in THF. After incubation 
samples were centrifuged at 14000 rpm and the supernatants were analyzed by High Resolution Mass 
Spectrometry as described in the bibliography [45]. 
3.4. Scale-Up Synthesis of BAS Polymers for Animal Experimentation 
The corresponding saccharide or mixture of saccharides (25 g) is dissolved in carbonate buffer  
(0.5 M pH 12, 2.5 L) under mechanical stirring (700 rpm). The addition of DVS (25 mL) was carried 
out dropwise and the cross-linking reaction was allowed to proceed overnight. The product was 
isolated by filtration and thoroughly washed with deionized water, with MeOH and finally with diethyl 
ether. The resulting cross-linked saccharide polymers were subjected to Soxhlet extraction with ethyl 
acetate to eliminate any trace of unreacted components and then dried in vacuo for 18 h at 50 °C. 
Samples were powered with a blender before addition to the diet. 
3.5. Characterization of the BAS Polymers Assayed in Animal Experimentation 
Elemental analyses (CHNS) were determined with an elemental analyzer Thermo Scientific Flash 2000 
(Thermo Scientific, Madrid, Spain). Electron microscopy examination was performed on samples 
covered with gold using a sputter coater (SEMPREP2, Technoorg Linda LTD, Budapest, Hungary) 
and electron micrographs were taken with a Hitachi S-510C scanning electron microscope at 3 kV 
(Hitachi High Technologies Europe GmbH, Krefeld, Germany. X-ray diffraction was carried out on a 
Philips Pw1710/00 diffractometer using Cu Kα radiation (Madrid, Spain). The operation voltage and 
current were 40 kV and 40 mA, respectively. Data were collected from 3° to 80° with a 0.04° step and 
0.4 s of integration. Data acquisition and processing were carried out with Xpowder diffraction 
software [46]. 
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3.6. Animal Experimentation 
All animal experiments were carried out in strict compliance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal care 
and experimental procedures were approved by the Animal Experimentation Ethics Committee (CEEA) 
of the University of Granada, Spain (Ref. 420-2012-CEEA). 
A total of 30 male Wistar rats weighing 100 g were randomly divided into 6 groups and they were 
given ad libitum access to food and water. The control group was fed exclusively with a conventional 
diet. The remaining five groups were fed with conventional diet supplemented with 2% (w/w) 
cholesterol for two weeks to induce hypercholesterolemia and then for two extra weeks with the same 
diet supplemented with 5% (w/w) of BAS polymer to assay. At the end of the experimental period 
animals were sacrificed by cervical dislocation and blood sample were taken for the analysis of 
cholesterol, triglycerides, glucose, creatinine and transaminases. Clinical Chemistry analyses were 
carried out by a certified veterinary laboratory. 
4. Conclusions 
The cross-linking of either β-CD, dextrin or starch with DVS yielded a library of insoluble homo- 
and hetero-polymers. Among the 22 polymer synthesized, three were identified as promising materials 
for their ability to trap CHOL and BA as well as for the yield of the synthesis. It is important to recall 
that two are neutral hetero-polymers of β-CD and starch (polymer 8) or dextrin (polymer 11) and the 
third is a weakly cationic homo-polymer of starch functionalized with bis(2-pyridylmethyl)amine, 
highlighting the importance of the cavity effect. In vivo assay on hypercholesterolemic rats reveals that 
the selected polymers yield similar reduced levels of CHOL. The analysis of the transaminase activity 
and the creatinine level does not detect any statistically significant difference compared to the control 
group, supporting the absence of toxicity. In general, the ability is these three polymers to regulate 
hypecholesterolemia is similar to that for the reference BAS cholestyramine, but with two additional 
advantages: (i) they normalize the TG level, and (ii) they do not increase the creatinine level. These 
results suggest that these polymers are good candidates to manage hypercholesterolemia.  
Acknowledgments 
Financial Support was provided by Universidad de Granada in the frame of the Granada Research 
of Excellence Initiative on BioHealth (GREIB). Authors are indebted to Daniel Martin Ramos for his 
assistance during the X-ray diffraction experiments and for providing XPOWDER free of charge.  
Author Contributions 
F.S.G., F.H.M. and F.J.L.J. conceived the study and oversaw the analysis. M.D.G.G. and R.S.G. 
carried out the animal experimentation. F.J.L.J. was responsible for the synthesis and screening of the 
library, the selection and characterization of the polymers that underwent animal experimentation, the 
preparation of the diets and drafted the manuscript. All authors read and approved the final manuscript. 
  
Molecules 2015, 20 3727 
 
 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Burden: Mortality, morbidity and risk factors. In Global Status Report on Noncommunicable 
Diseases 2010; Alwan, A., Ed.; World Health Organization: Geneva, Switzerland, 2011; pp. 9–11. 
Available online: http://www.who.int/nmh/publications/ncd_report_full_en.pdf (accessed on 4 
November 2014). 
2. Rideout, T.C.; Hading, S.V.; Marinangeli, C.P.F.; Jones, P.J.H. Combination drug–diet therapies 
for dyslipidemia. Transl. Res. 2010, 155, 220–227. 
3. Rozman, D.; Monostory, K. Perspectives of the non-statin hypolipidemic agents. Pharmacol. Ther. 
2010, 127, 19–40. 
4. Brautbar, A.; Ballantyne, C.M. Pharmacological strategies for lowering LDL cholesterol: Statins 
and beyond. Nat. Rev. Cardiol. 2011, 8, 253–265. 
5. Tiwari, V.; Khokhar, M. Mechanism of action of anti-hypercholesterolemia drugs and their 
resistance. Eur. J. Pharmacol. 2014, 741, 156–170. 
6. Staels, B.; Fonseca, V.A. Bile acids and metabolic regulation. Diabetes Care 2009, 32, S237–S245. 
7. Van der Wulp, M.Y.M.; Verkade, H.J.; Groen, A.K. Regulation of cholesterol homeostasis.  
Mol. Cell. Endocrinol. 2013, 368, 1–16. 
8. Mendoza, P.V.; Serra, A.C.; Silva, C.L.; Simoes, S.; Coelho, J.F.J. Polymeric bile acid 
sequestrants. Synthesis using conventional methods and new approaches based on 
“controlled”/living radical polymerization. Prog. Polym. Sci. 2013, 38, 445–461. 
9. Nichifor, M.; Zhu, X.X.; Baille, W.; Cristea, D.; Carpov, A. Bile acid sequestrants based on 
cationic dextran hydrogel microspheres. 2. Influence of the length of alkyl substituents at the 
amino groups of the sorbents on the sorption of bile salts. J. Pharm. Sci. 2001, 90, 681–689. 
10. Nichifor, M.; Cristea, D.; Carpov, A. Sodium cholate sorption on cationic dextran hydrogel 
microspheres. 1. Influence of the chemical structure of functional groups. Int. J. Biol. Macromol. 
2000, 28, 15–21. 
11. Lee, J.K.; Kim, S.Y.; Kim, S.U.; Kim, J.H. Synthesis of cationic polysaccharide derivatives and 
their hypocholesterolaemic capacity. Biotechnol. Appl. Biochem. 2002, 35, 181–189. 
12. Lee, J.K.; Kim, S.U.; Kim, J.H. Modification of chitosan to improve its hypocholesterolemic 
capacity. Biosci. Biotechnol. Biochem. 1999, 63, 833–839. 
13. Murata, Y.; Kodoma, Y.; Hirai, D.; Kofugi, K.; Kawashima, S. Properties of an oral preparation 
containing a chitosan salt. Molecules 2009, 14, 755–762. 
14. Loftsson, T.; Brewster, E. Pharmaceutical applications of cyclodextrins: Effects on drug 
permeation through biological membranes. J. Pharm. Pharmacol. 2011, 63, 1119–1135. 
15. Loftsson, T.; Brewster, E. Cyclodextrins as Functional Excipients: Methods to Enhance 
Complexation Efficiency. J. Pharm. Sci. 2012, 101, 3019–3032. 
16. Favier, M.L.; Memesy, C.; Moundras, C.; Demigne, C. Effect of cyclodextrin on plasma lipids 
and cholesterol metabolism in the rat. Metabolism 1995, 44, 200–206. 
Molecules 2015, 20 3728 
 
 
17. Trautwein, E.A.; Forgbert, K.; Rieckhoff, D.; Erbersdobler, H.F. Impact of beta-cyclodextrin and 
resistant starch on bile acid metabolism and fecal steroid excretion in regard to their 
hypolipidemic action in hamsters. Biochim. Biophys. Acta 1999, 1437, 1–12. 
18. Garcia-Mediavilla, V.; Villares, C.; Culebras, J.M.; Bayón, J.E.; Gonzalez-Gallego, J. Effects of 
dietary β-cyclodextrin in hypercholesterolemic rats. Pharmacol. Toxicol. 2003, 92, 94–99. 
19. Park, B.S.; Jang, A. Effects of Dietary β-Cyclodextrin on Plasma Lipid and Tissue Cholesterol 
Content in Swine. Asian-Aust. J. Anim. Sci. 2007, 20, 100–105. 
20. Kang, H.K.; Park, B.S. Cholesterol Contents of Pork Fed Dietary β-Cyclodextrin. J. Korean Soc. 
Food Sci. Nutr. 2007, 36, 180–185. 
21. Wagner, E.M.; Jen, K.L.C.; Artiss, J.D.; Remaley, A.T. Dietary α-cyclodextrin lowers low-density 
lipoprotein cholesterol and alters plasma fatty acid profile in low-density lipoprotein receptor 
knockout mice on a high-fat diet. Metabolism 2008, 57, 1046–1051. 
22. Abadie, C.; Hug, M.; Kübli, C.; Gains, N. Effect of cyclodextrins and undigested starch on the 
loss of chenodeoxycholate in the faeces. Biochem. J. 1994, 299, 725–730. 
23. Evaluation of Oral Alpha-Cyclodextrin for Decreasing Seum Cholesterol. Available online: 
http://clinicaltrials.gov/show/NCT01131299 (accessed on 4 November 2014). 
24. Van Der Manakker, F.; Vermonden, T.; van Nostrum, C.F.; Hennink, W.E. Cyclodextrin-based 
polymeric materials: Synthesis, properties, and pharmaceutical/biomedical applications. 
Biomacromolecules 2009, 10, 3157–3175. 
25. Hoang Thi, T.H.; Chai, F.; Lepretre, S.; Blanchemain, N.; Martel, B.; Siepmann, F.; Hildebrand, H.F.; 
Siepmann, J.; Flament, M.P. Bone implants modified with cyclodextrin: Study of drug release in 
bulk fluid and into agarose gel. Int. J. Pharm. 2010, 400, 74–85. 
26. Blanchemain, N.; Karrout, Y.; Tabary, N.; Neut, C.; Bria, M.; Siepmann, J.; Hildebrand, H.F.; 
Martel, B. Methyl-beta-cyclodextrin modified vascular prosthesis: Influence of the modification 
level on the drug delivery properties in different media. Acta Biomater. 2011, 7, 304–314. 
27. Ji, J.G.; Zhang, J.F.; Hao, S.L.; Wu, D.-J.; Liu, L.; Xu, Y. Preparation, Characterization of 
Hydrophobic Drug in Combine Loaded Chitosan/Cyclodextrin/Trisodium Citrate Nanoparticles 
and in vitro Release Study. Colloids Surf. B 2011, 83, 103–107. 
28. Anand, R.; Malanga, M.; Manet, I.; Manoli, F.; Tuza, K.; Aykac, A.; Ladaviere, C.; Fenyvesi, E.; 
Vargas-Berenguel, A.; Gref, R.; et al. Citric acid–γ-cyclodextrin crosslinked oligomers as carriers 
for doxorubicin delivery. Photochem. Photobiol. Sci. 2013, 12, 1841–1854.  
29. Morales-Sanfrutos, J.; Lopez-Jaramillo, F.J.; Elremaily, M.A.A.; Hernandez-Mateo, F.;  
Santoyo-Gonzalez, F. Divinyl sulfone cross-linked cyclodextrin-based polymeric materials: 
Synthesis and applications as sorbents and encapsulating agents. Molecules 2015, 20, 3565–3581. 
30. Baile, W.E.; Huang, W.Q.; Nichifor, M.; Zhu, X.X. Functionalized β-cyclodextrin polymers for 
the sorption of bile salts. J. Macromol. Sci. Part A: Pure Appl. Chem. 2000, 37, 677–690. 
31. Gylling, H.M.; Mietinnen, T.A. The effect of cholesterol absorption inhibition on low density 
lipoprotein cholesterol level. Atherosclerosis 1995, 117, 305–308. 
32. Staels, B.; Handelsman, Y.; Fonseca, V. Bile acid sequestrants for lipid and glucose control.  
Curr. Diab. Rep. 2010, 10, 70–77. 
33. Forristal, I. The chemistry of α,β-unsaturated sulfoxides and sulfones: An update. J. Sulfur Chem. 
2005, 26, 163–195. 
Molecules 2015, 20 3729 
 
 
34. Aows, D.C.; Gervay-Hague, J. Vinyl sulfones: Synthetic preparations and medicinal chemistry 
applications. Med. Res. Rev. 2006, 26, 793–814. 
35. Comini, S.; Olivier, P.; Riottot, M.; Duhamel, D. Interaction of β-cyclodextrin with bile acids and 
their competition with vitamins A and D3 as determined by 1H-NMR spectroscopy. Clin. Chim. Acta 
1994, 228, 181–194. 
36. Weingärtner, O.; Lütjohann, D.; Böhm, M.; Laufs, U. Relationship between cholesterol synthesis 
and intestinal absorption is associated with cardiovascular risk. Artherosclerosis 2010, 210, 362–365. 
37. Han, E.M.; Kim, S.H.; Ahn, J.; Kwak, H.S. Comparison of cholesterol-reduced cream cheese 
manufactured using crosslinked β-cyclodextrin to regular cream cheese. Asian-Australas J. Anim. Sci. 
2008, 21, 131–137. 
38. Shonbeck, C.; Westh, P.; Madsen, J.C.; Larsen, K.L.; Stade, L.W.; Holm, R. Methylated  
β-Cyclodextrins: Influence of degree and pattern of substitution on the thermodynamics of 
complexation with tauro- and glyco-conjugated bile salts. Langmuir 2011, 27, 5832–5841. 
39. Hinrichs, W.; Buttner, G.; Steifa, M.; Betzel, C.H.; Zabel, V.; Pfannemuller, B.; Saenger, W. An 
amylose antiparallel double helix at atomic resolution. Science 1987, 238, 205–208. 
40. Boehm, O.; Zur, B.; Koch, A.; Tran, N.; Freyenhagen, R.; Harmann, M.; Zacharowski, K. Clinical 
chemistry reference database for Wistar rats anc C57/BL7 mice. Biol. Chem. 2007, 388, 547–554. 
41. Angelin, B.; Eriksson, M.; Rudling, M. Bile acids and lipoprotein metabolism: A renaissance for 
bile acids in the post-statin era? Curr. Opin. Lipidol. 1999, 10, 269–274. 
42. Hagen, E.; Istad, H.; Ose, L.; Bodd, E.; Eriksen, H.M.; Selvig, V.; Bard, J.M.; Fruchart, J.C.; 
Borge, M.; Wolf, M-C; et al. Fluvastatin efficacy and tolerability in comparison and in 
combination with cholestyramine. Eur. J. Clin. Pharmacol. 1994, 46, 445–449. 
43. Favier, M.-L.; Moundras, C.; Demigne, C.; Remesy, C. Fermentable carbohydrates exert a more 
potent cholesterol-lowering effect than cholestyramine. Biochim. Biophys. Acta 1995, 1258, 115–121. 
44. Leonard, T.B.; Naptun, D.A.; Popp, J.A. Serum gamma glutamyl transferase as a specific 
indicator of bile duct lesions in the rat liver. Am. J. Pathol. 1984, 116, 262–269.  
45. Scherer, M.; Gnewuch, C.; Schmitz, G.; Liebisch, G. Rapid quantification of bile acids and their 
conjugates in serum by liquid chromatography–tandem mass spectrometry. J. Chromatogr. B 
2009, 877, 3920–3925. 
46. Martin, J.D. Using XPowder: A software package for powder X-ray diffraction analysis;  
ISBN 84-609-1497-6; Spain, 2004; Available online: http://www.xpowder.com (accessed on  
10 October 2014). 
Sample Availability: Not available. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
 
